Pliant Therapeutics, Inc. PLRX
1.08
(0.06)
(5.26%)
as of 25 Sep
- Market cap
- $70.6M
- P/E
- 0.0×
Follow PLRX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
13.72 | 11.67 | 16.50 | 9.59 | |
Current Ratio |
13.93 | 12.00 | 16.89 | 9.90 | |
Net Debt/EBITDA |
7.69 | 8.33 | 8.10 | 6.66 | |
Debt/Assets |
11.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.15 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.80 | 0.75 | 0.96 | 0.57 | |
Capex/Depreciation |
0.20 | 0.00 | 0.15 | 0.13 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.34) | (0.29) | (0.31) | (0.21) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.34) | (0.29) | (0.31) | (0.21) | |
Cash per Share |
3.94 | 3.11 | 2.77 | 2.55 | |
Shareholders Equity per Share |
3.26 | 2.95 | 2.67 | 2.37 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.26 | 2.95 | 2.67 | 2.37 | |
Free Cash Flow |
(20.92) | (17.79) | (19.13) | (12.78) | |
Working Capital |
227.96 | 180.08 | 164.57 | 146.66 | |
Capital Expenditures |
0.16 | 0.00 | 0.10 | 0.02 | |
Net Current Asset Value |
169.29 | 152.43 | 137.50 | 120.19 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
| Other line items | |||||
Average Payables |
3.69 | 3.22 | 2.99 | 1.46 | |
Average Assets |
361.13 | 311.09 | 273.68 | 244.85 | |
Average Common Equity |
273.06 | 242.64 | 211.16 | 183.50 |
Columns are period end dates